Favipiravir

Generic Name: Favipiravir

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₅H_₄FN_₃O_₂

CAS Number: 259793-96-9

Unique Ingredient Identifier: EW5GL2X7E0

Background: Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.
...

Indication: ⑴用于埃博拉病毒感染的治疗。

⑵用于治疗成人新型或再次流行的流感（仅限于其他抗流感病毒药物治疗无效或效果不佳时使用）

Associated Conditions: Treatment resistant Novel Influenza, Treatment resistant Reemerging Influenza

Associated Therapies: -

Clinical Trials

Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Other: Standard of Care
Drug: Favipiravir

First Posted Date: 2020-04-24

Last Posted Date: 2022-03-29

Lead Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc.

Target Recruit Count: 50

Registration Number: NCT04358549

Locations: 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

and more 5 locations

Efficacy of Faviprevir in COVID-19 Treatment

Phase 2

Completed

Conditions: COVID

Interventions: Drug: Favipiravir
Drug: Chloroquine

First Posted Date: 2020-04-17

Last Posted Date: 2021-11-01

Lead Sponsor: Tanta University

Target Recruit Count: 92

Registration Number: NCT04351295

Locations: 🇪🇬
Tanta University, Ainshams University, Tanta, Egypt

Efficacy and Safety of Favipiravir in Management of COVID-19

Phase 3

Completed

Conditions: Coronavirus Disease (COVID-19)

Interventions: Drug: Standard of care therapy
Drug: favipiravir

First Posted Date: 2020-04-16

Last Posted Date: 2020-06-25

Lead Sponsor: Ain Shams University

Target Recruit Count: 100

Registration Number: NCT04349241

Locations: 🇪🇬
Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt

Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19

Phase 2

Completed

Conditions: COVID-19
Sars-CoV2

Interventions: Drug: Favipiravir
Drug: Placebo
Other: Standard of care treatment

First Posted Date: 2020-04-15

Last Posted Date: 2022-07-13

Lead Sponsor: Stanford University

Target Recruit Count: 149

Registration Number: NCT04346628

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19

Phase 3

Conditions: COVID-19

Interventions: Other: Placebo
Drug: Favipiravir

First Posted Date: 2020-04-07

Last Posted Date: 2020-04-08

Lead Sponsor: Giuliano Rizzardini

Target Recruit Count: 100

Registration Number: NCT04336904

Locations: 🇮🇹
Asst Fatebenefratelli Sacco, Milano, Italy

Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive

Not Applicable

Conditions: COVID-19

Interventions: Drug: Favipiravir

First Posted Date: 2020-04-03

Last Posted Date: 2020-04-24

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 210

Registration Number: NCT04333589

Locations: 🇨🇳
Ezhou Central Hospital, Wuhan, Hubei, China
🇨🇳
Jinyintan Hospital of Wuhan, Wuhan, Hubei, China
🇨🇳
Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China

and more 5 locations

Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019

Not Applicable

Conditions: COVID-19

Interventions: Drug: Favipiravir Combined With Tocilizumab
Drug: Favipiravir
Drug: Tocilizumab

First Posted Date: 2020-03-17

Last Posted Date: 2020-04-10

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 150

Registration Number: NCT04310228

Locations: 🇨🇳
Guiqiang Wang, Beijing, Beijing, China
🇨🇳
Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China
🇨🇳
Jinyintan Hospital of Wuhan, Wuhan, Hubei, China

and more 3 locations

A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza

Phase 2

Completed

Conditions: Influenza, Human
Influenza
Critical Illness

Interventions: Drug: Favipiravir
Drug: Oseltamivir 75Mg Capsule

First Posted Date: 2018-01-09

Last Posted Date: 2019-05-15

Lead Sponsor: Capital Medical University

Target Recruit Count: 34

Registration Number: NCT03394209

Locations: 🇨🇳
China-Japan Friendship Hospital, Beijing, China

Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen

Phase 2

Terminated

Conditions: Ebola Virus Survivor

Interventions: Drug: Favipiravir

First Posted Date: 2016-04-15

Last Posted Date: 2018-10-18

Lead Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Target Recruit Count: 2

Registration Number: NCT02739477

Locations: 🇬🇳
Nzérékoré, Nzérékoré, Guinea
🇬🇳
Conakry, Conakry, Guinea

Efficacy of Favipiravir Against Severe Ebola Virus Disease

Phase 2

Completed

Conditions: Ebola Virus Disease

Interventions: Other: WHO-recommended therapies
Drug: Favipiravir

First Posted Date: 2016-01-26

Last Posted Date: 2016-01-26

Lead Sponsor: Beijing Institute of Pharmacology and Toxicology

Target Recruit Count: 77

Registration Number: NCT02662855

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy